Dr Sue Cammarata has joined Melinta Therapeutics as chief medical officer as the company advances the progress of its late-stage pipeline.
In her new role, Dr Cammarata will lead the company’s global development and registration strategy, including the plan for lead product candidate delafloxacin, in phase III for skin infections.
She has prior experience in developing anti-infectives, including Cubicin (daptomycin) during her time at Novartis, where she served as VP and global programme head for the company’s immunology and infectious disease franchises from 2008 to 2010.
Dr Cammarata spent seven years at Novartis in total, having joined the company from Pharmacia in 2003. At Pharmacia, she worked on the anti-infective Zyvox (linezolid).
Her most recent role prior to joining Melinta was as VP, clinical research at Shire’s human genetic therapies division.
Melinta’s CEO Mary Szela said: “The extensive expertise Sue gained while developing and commercialising Cubicin and Zyvox, two billion-dollar anti-infective products that are among the most widely prescribed, will be invaluable as we move our earlier stage antimicrobial candidates into and through the clinic.”